I am sending all the questions to Todd and Joe.
Post# of 36568
(Total Views: 356)
Posted On: 07/08/2020 11:03:32 AM
I am sending all the questions to Todd and Joe.
Here is a response note from Todd:
Hello Dr. XXXXXX
I hope you are well.
We appreciate everything you provide to us & I personally thank you.
This call is the first NuGenerex Immuno-Oncology Conference Call, and the agenda is specifically set to introduce and address NuGenerex Immuno-Oncology initiatives.
Yes, Generex Biotechnology Corp. is the parent company of NuGenerex Immuno-Oncology and Joe will address issues that bridge between the 2 companies, and as always Joe will be as open and forthright as possible with all investors and persons of interest.
That said, Generex Biotechnology Corp. & our NuGenerex Family of Subsidiary Companies are at the end of a 3.5-year corporate restructuring, that includes regulatory approvals on a wide variety of corporate items.
Internally we are working very hard and have stayed relatively quiet the past few months as we work through the process. This is done purposely, we don’t want any misunderstandings or misinterpretations that might negatively affect what we are working to complete.
There are many items to talk about including further acquisitions, the overall corporate structure, and the synergistic effect and advantages they will bring to Generex Biotechnology Corp. & our NuGenerex Family of Companies.
The filings made over the past 2 to 3 weeks represents the culmination of our corporate restructuring and the first NuGenerex Immuno-Oncology conference call represents the beginning of our next chapter and eagerly anticipated future success.
Further Conference Calls and Press Release at the frequency of the past, are imminent.
If you have any specific questions please don’t hesitate to call.
Regards,
Todd Falls
Here is a response note from Todd:
Hello Dr. XXXXXX
I hope you are well.
We appreciate everything you provide to us & I personally thank you.
This call is the first NuGenerex Immuno-Oncology Conference Call, and the agenda is specifically set to introduce and address NuGenerex Immuno-Oncology initiatives.
Yes, Generex Biotechnology Corp. is the parent company of NuGenerex Immuno-Oncology and Joe will address issues that bridge between the 2 companies, and as always Joe will be as open and forthright as possible with all investors and persons of interest.
That said, Generex Biotechnology Corp. & our NuGenerex Family of Subsidiary Companies are at the end of a 3.5-year corporate restructuring, that includes regulatory approvals on a wide variety of corporate items.
Internally we are working very hard and have stayed relatively quiet the past few months as we work through the process. This is done purposely, we don’t want any misunderstandings or misinterpretations that might negatively affect what we are working to complete.
There are many items to talk about including further acquisitions, the overall corporate structure, and the synergistic effect and advantages they will bring to Generex Biotechnology Corp. & our NuGenerex Family of Companies.
The filings made over the past 2 to 3 weeks represents the culmination of our corporate restructuring and the first NuGenerex Immuno-Oncology conference call represents the beginning of our next chapter and eagerly anticipated future success.
Further Conference Calls and Press Release at the frequency of the past, are imminent.
If you have any specific questions please don’t hesitate to call.
Regards,
Todd Falls
(5)
(0)